Navigation Links
WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels

FREMONT, Calif., Jan. 10, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced general availability of its Quick-Turnaround SmartChip Custom Panels to enable validation studies of specific genes of interest through customization of high-throughput, real-time PCR SmartChip assay panels -- all on a Quick-Turnaround basis.

Using the SmartChip Custom Panels, WaferGen can now offer researchers -- on a Quick Turnaround basis -- their own application-specific real-time PCR assay panel.  Customers can choose from WaferGen's existing library of assays, or have WaferGen develop a panel for them. The WaferGen scientific team will design, optimize, and deliver SmartChip Custom Panels with tens to hundreds of assays repeated across the chip.  Custom panels allow customers to save time and money on real-time PCR validation studies compared to traditional methods by enabling hundreds of samples at a cost of $10s to $100s per sample in a single experiment.  The Quick-Turnaround SmartChip Custom Panels become a valuable tool in enabling researchers to validate biomarkers coming from genome-wide Next Generation Sequencing (NGS) discovery programs.

"We continue to enhance our SmartChip genomics analysis solution with additional gene panel offerings," said Alnoor Shivji, Chairman and CEO.  "Our custom panels with quick turnaround time will enable researchers to conduct large-scale validation studies with unmatched speed and cost advantages.  We now offer the ability to run up to 384 samples on a single SmartChip, offering the maximum flexibility to researchers involved in biomarker validation studies. Combined with our growing breadth of validated gene expression assays, the SmartChip Custom Panels contribute to the SmartChip System becoming an industry-leading validation platform for biomarker discovery studies."  

About WaferGen and the SmartChip Real-Time PCR SystemWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries.  The company currently offers the breakthrough SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that SmartChip is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing.  In addition, the high throughput capabilities of the SmartChip System enable researchers to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, the SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System.  For additional information, please see

Forward-Looking Statements This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits of the SmartChip Real-Time PCR System with respect to next generation sequencing and health care costs, statements relating to the expected benefits and advantages of the SmartChip service for gene-expression research, statements relating to the expected benefits and advantages of the SmartChip technology, including the SmartChip Custom Panels, to other applications, statements relating to the company's belief that the SmartChip System is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing, statements relating to the company's belief that its product is poised to become an industry-leading validation platform for biomarker discovery projects, and other statements relating to future events that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.  Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively.  More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the most recent Form 10-Q.  Investors and security holders are urged to read this document free of charge on the SEC's web site at  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Contacts:WaferGen510-651-4450Don Huffman, CFOdon.huffman@wafergen.comJoyce

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
2. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference
3. WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System
4. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
5. WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Companys Scientific Advisory Board
6. WaferGen Closes on Private Financings of Approx. $6.2 Million
7. WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference
8. Data on WaferGens SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference
9. WaferGen Announces Signing of Private Financing
10. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
11. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):